Aeolus reports positive results from Lou Gehrig’s drug study
AEOL 10150 is one of a potential new class of disease-modifying compounds based on small molecule catalytic antioxidants being developed by the company. The compound mimics and amplifies
AEOL 10150 is one of a potential new class of disease-modifying compounds based on small molecule catalytic antioxidants being developed by the company. The compound mimics and amplifies
Oxxon’s proprietary PrimeBoost platform is an approach that allows rapid development of products to selectively stimulate and enhance a potent cellular response. The recent phase II study showed
Bonviva (ibandronic acid), known as Boniva in the US, is the first and only once-monthly tablet for the treatment of postmenopausal osteoporosis. The Swiss acceptance marks the first
The objectives of this clinical trial are to establish the safety, dose and preliminary efficacy of IPdR in combination with radiation therapy in colorectal, gastric, pancreatic and liver
The new 1.2 million square foot campus known as Grange Castle will be used to produce the company’s key biotech products and to research new drugs. Ireland has
Clusterin is a protein found in tumor cells that, when overexpressed, causes resistance to cell death induced by standard anticancer therapies. The study concluded that OGX-011, targeted to
Subject to FDA acceptance, Avalon plans to begin its first US phase I clinical trial of AVN944 in patients with hematologic malignancies. “We believe the results of the
The company hopes that these biomarkers can be developed into a test that will allow early diagnosis of amyotrophic lateral sclerosis (ALS). ALS is a fatal neurodegenerative disease,
The dose-ranging trial, which is being conducted in Germany, will enroll 48 volunteers and will involve the testing of three different doses over 20 days. Completion of the
Under this collaboration, Celera Diagnostics and Merck will combine their research efforts in the genetics of this devastating brain disease to genetically validate and prioritize a series of